CD99 and acute myeloid leukemia: The evidence provided here that FOXM1 may be inhibited through the targeting of a cell surface molecule, like CD99, may offer a promising alternative for those tumors that overexpress CD99 (i.e., EwS, glioma, melanoma, and acute myeloid leukemia)48, 49